GuidelineThorax2016
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.
Guideline in Thorax, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03339063 (The Italian Registry of Pulmonary Non-tuberculous Mycobacteria), which is not on this map. Cited by 219 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Italian Registry of Pulmonary Non-tuberculous Mycobacteria
Who cites it
219 citing papers in PubMed, 4 syntheses or guidelines pooled it, 463 citations in OpenAlex.
- A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.The Cochrane database of systematic reviews · 2025Pooled it
- Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.International forum of allergy & rhinology · 2022Pooled it
- Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.The Cochrane database of systematic reviews · 2019Pooled it
- Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI).Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Trial
- Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.Clinical pharmacokinetics · 2024Trial
- Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates.Scientific reports · 2021Trial
- Interferon-γ-response to mycobacterial glycopeptidolipids in patients with pulmonary non-tuberculous mycobacterial infection.Medical microbiology and immunology · 2026Article
- DNA sequencing for microbial surveillance in cystic fibrosis airways: advances, challenges, and clinical translation.Clinical microbiology reviews · 2026Review
- Clofazimine use for nontuberculous mycobacterial infections: 10-year experience in Belgium.BMC pulmonary medicine · 2026Observational
- Experimental evolution in the cystic fibrosis chemical environment reveals early TCA cycle flux as a central regulator ofBiofilm · 2026Article
- Chemoproteomic Elucidation of β-Lactam Drug Targets inACS infectious diseases · 2026Article
- Injection-Site Abscess Caused by Mycobacterium abscessus Following Testosterone Injection: A Case Report.Cureus · 2026Article
- Physical compatibility of omadacycline with intravenous agents used in the treatment of Mycobacteroides abscessus pulmonary disease.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026Article
- From colonisation to chronicity: adaptation ofMicrobiology (Reading, England) · 2026Article
- Protective mechanism of action of the antifungal drug naftifine againstAntimicrobial agents and chemotherapy · 2026Article
- Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes.Nature microbiology · 2026Article
- In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates.The Journal of antimicrobial chemotherapy · 2026Article
- Phosphatidylserine liposomes forFrontiers in immunology · 2026Article
- Diagnostic Yield of Nontuberculous Mycobacteria Testing in Patients with Chronic Lung Diseases: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
159 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 18 institutions in 5 countries.
Funding
Abstract
Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease such as cystic fibrosis (CF). Pulmonary disease caused by NTM has emerged as a major threat to the health of individuals with CF but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened an expert panel of specialists to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM pulmonary disease in individuals with CF. Nineteen experts were invited to participate in the recommendation development process. Population, Intervention, Comparison, Outcome (PICO) methodology and systematic literature reviews were employed to inform draft recommendations. An anonymous voting process was used by the committee to reach consensus. All committee members were asked to rate each statement on a scale of: 0, completely disagree, to 9, completely agree; with 80% or more of scores between 7 and 9 being considered 'good' agreement. Additionally, the committee solicited feedback from the CF communities in the USA and Europe and considered the feedback in the development of the final recommendation statements. Three rounds of voting were conducted to achieve 80% consensus for each recommendation statement. Through this process, we have generated a series of pragmatic, evidence-based recommendations for the screening, investigation, diagnosis and treatment of NTM infection in individuals with CF as an initial step in optimising management for this challenging condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.